Development of the combined immunotherapy; immune checkpoint inhibitor and cancer vaccine
| Project/Area Number |
17H04410
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Tsurumi University (2019)
Osaka University (2017-2018) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2019: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2018: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2017: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
|
|---|
| Keywords | 癌ワクチン / 免疫チェックポイント阻害剤 / 樹状細胞 / 複合免疫療法 / 口腔癌 / 癌免疫療法 / PD-1 / 免疫チェックポイント / WT1 |
|---|
| Outline of Final Research Achievements |
We investigated the effect of the combined immunotherapy with the cancer vaccine using dendritic cells (DC) and the immune checkpoint inhibitor. In in vitro experiment, induction of cytotoxic T lymphocytes (CTLs) against WT1, which was reported to be expressed in oral squamous cell carcinoma cells, was enhanced by the combined use of anti-PD-1 antibody. In in vivo study using syngeneic tumor-bearing mice, stronger anti-tumor effect was observed by the treatment with WT1 pulsed DC vaccine and anti-PD-1 antibody as compared with DC vaccine alone or anti-PD-1 antibody alone. We conducted a pilot study of the combination therapy with anti-PD-1 antibody + cancer antigen pulsed DC vaccine. Up to now, 6 patients with unresectable oral cancer have been treated with the same method and are under observation. In all cases, induction of CTL specific for at least one cancer antigen used was confirmed. We plan to continue expanding the number of cases.
|
| Academic Significance and Societal Importance of the Research Achievements |
オプジーボやキィトルーダ等の免疫チェックポイント阻害剤による癌治療効果が明らかになり癌に対する免疫療法が注目されている。しかしな、免疫チェックポイント阻害剤の治療効果は15～25％程度であり決して満足できるものではない。さらなる治療効果向上の為に癌ワクチンとの併用が期待されている。本研究結果にて、樹状細胞ワクチンと免疫チェックポイント阻害剤の併用が非常に効果的である可能性が強く示唆され、より有効な癌治療法の開発に寄与すると考えられる。
|
Report
(4 results)
Research Products
(31 results)
-
-
-
-
[Journal Article] Feasibility and immune response of WT1 peptide vaccine in combination with OK-432 for pediatric solid tumours2018
Author(s)
4.Hirabayashi K, Yanagisawa R, Saito S, Higuchi Y, Koya T, Sano K, Koido S, Okamoto M, Sugiyama H, Nakazawa Y, Shimodaira S
-
Journal Title
Anticancer Res
Volume: 38
Pages: 2227-2234
Related Report
Peer Reviewed
-
-
[Journal Article] Prognostic significance of Wilms’ tumor 1 expression in patients with pancreatic ductal adenocarcinoma2018
Author(s)
2.Kanai T, Ito Z, Oji Y, Suka M, Nishida S, Takakura K, Kajihara M, Fujioka S, Misawa T, Akiba T, Yanagisawa H, Saruta M, Okamoto M, Sugiyama H, Koido S
-
Journal Title
Oncol Lett
Volume: 16
Pages: 2682-2692
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.2017
Author(s)
Fukuda K, Funakoshi T, Sakurai T, Nakamura Y, Mori M, Tanese K, Tanikawa A, Taguchi J, Fujita T, Okamoto M, Amagai M, Kawakami Y.
-
Journal Title
Melanoma Research.
Volume: in press
Issue: 4
Pages: 326-334
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
